Security
Arrowhead Pharmaceuticals, Inc. Common Stock · ARWR
ARWRNASDAQCommon stockCurrentCIK 879407Updated Oct 6, 2026
Name history
ARROWHEAD RESEARCH CORP · through Apr 6, 2016INTERACTIVE GROUP INC · through Jan 9, 2004INTERACTIVE INC · through Feb 13, 2002
ARWR price & chart
Loading TradingView…
NASDAQ:ARWR on TradingView ↗About the company
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.
In the news
Seeking Alpha
Ionis upgraded at BMO on Tryngolza adoption for severe hypertriglyceridemia ↗
Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform ↗
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript ↗
Recent filings
144 filing
144 filing
SCHEDULE 13G/A - filed by Avoro Capital Advisors LLC regarding ARROWHEAD PHARMACEUTICALS, INC.
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Show 5 more recent filings
SCHEDULE 13G/A - filed by VANGUARD PORTFOLIO MANAGEMENT LLC regarding ARROWHEAD PHARMACEUTICALS, INC.
SCHEDULE 13G/A - filed by BlackRock, Inc. regarding ARROWHEAD PHARMACEUTICALS, INC.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
144/A filing
144/A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 2,112,013,000Source | 1,380,612,000Source | 883,759,000Source | 2,268,265,000Source | 1,573,498,000Source | 955,150,000Source | 1,604,181,000Source | 1,013,694,000Source | 1,385,295,000Source | 1,139,802,000Source | 765,552,000Source | 691,939,000Source |
| Property, Plant and Equipment, NetUSD | 373,301,000Source | 381,048,000Source | 375,911,000Source | 374,822,000Source | 384,803,000Source | 359,252,000Source | 378,584,000Source | 387,069,000Source | 382,515,000Source | 386,032,000Source | 290,262,000Source | 110,297,000Source |
| Current assets: | ||||||||||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 8,556,000Source | 9,699,000Source | 0Source | 15,685,000Source | 2,365,000Source | 0Source | 218,871,000Source | 2,500,000Source | 6,824,000Source | 0Source | 0Source | 1,410,000Source |
| Assets, CurrentUSD | 1,671,411,000Source | 946,923,000Source | 450,062,000Source | 1,839,751,000Source | 1,135,220,000Source | 541,650,000Source | 1,174,389,000Source | 570,536,000Source | 950,639,000Source | 695,471,000Source | 419,521,000Source | 405,299,000Source |
| Operating Lease, Right-of-Use AssetUSD | 55,667,000Source | 44,002,000Source | 44,339,000Source | 42,794,000Source | 44,452,000Source | 44,626,000Source | 43,361,000Source | 44,869,000Source | 43,891,000Source | 45,255,000Source | 45,297,000Source | 58,291,000Source |
| Other Assets, NoncurrentUSD | 6,048,000Source | 1,353,000Source | 4,460,000Source | 4,887,000Source | 1,312,000Source | 210,000Source | 1,411,000Source | 3,083,000Source | 1,389,000Source | 4,482,000Source | 210,000Source | 218,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 237,000Source | 230,000Source | 217,000Source | 236,000Source | 230,000Source | 217,000Source | 233,000Source | 218,000Source | 231,000Source | 217,000Source | 200,000Source | 198,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,923,355,000Source | -1,603,404,000Source | -1,454,987,000Source | -1,729,075,000Source | -1,428,163,000Source | -1,284,194,000Source | -1,596,343,000Source | -1,798,608,000Source | -1,627,154,000Source | -1,625,523,000Source | -1,026,030,000Source | -820,755,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,234,000Source | 5,357,000Source | -987,000Source | 742,000Source | 4,390,000Source | -1,095,000Source | 6,699,000Source | 4,137,000Source | 6,443,000Source | 4,750,000Source | -3,222,000Source | -136,000Source |
| Stockholders' Equity Attributable to ParentUSD | 465,529,000Source | 522,313,000Source | 330,547,000Source | 613,977,000Source | 683,321,000Source | 483,794,000Source | 568,422,000Source | 52,589,000Source | 466,052,000Source | 185,444,000Source | 271,343,000Source | 398,520,000Source |
| Additional Paid in Capital, Common StockUSD | 2,443,074,000Source | 2,120,130,000Source | 1,786,304,000Source | 2,395,267,000Source | 2,106,864,000Source | 1,768,866,000Source | 2,211,026,000Source | 1,846,842,000Source | 2,139,725,000Source | 1,806,000,000Source | 1,300,395,000Source | 1,219,213,000Source |
| Liabilities and EquityUSD | 2,112,013,000Source | 1,380,612,000Source | 883,759,000Source | 2,268,265,000Source | 1,573,498,000Source | 955,150,000Source | 1,604,181,000Source | 1,013,694,000Source | 1,385,295,000Source | 1,139,802,000Source | 765,552,000Source | 691,939,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 283,346,000Source | 194,530,000Source | 96,714,000Source | 295,220,000Source | 220,541,000Source | 65,175,000Source | 347,425,000Source | 93,758,000Source | 195,487,000Source | 103,168,000Source | 105,456,000Source | 138,850,000Source |
| Operating Lease, Liability, CurrentUSD | 5,322,000Source | 7,010,000Source | 6,053,000Source | 7,774,000Source | 6,782,000Source | 5,285,000Source | 7,529,000Source | 6,560,000Source | 7,289,000Source | 6,342,000Source | 10,563,000Source | 2,776,000Source |
| Accounts Payable, CurrentUSD | 27,776,000Source | 33,050,000Source | 26,550,000Source | 30,747,000Source | 9,980,000Source | 8,521,000Source | 32,937,000Source | 14,457,000Source | 17,674,000Source | 11,388,000Source | 35,866,000Source | 2,868,000Source |
| Operating Lease, Liability, NoncurrentUSD | 114,298,000Source | 105,690,000Source | 112,040,000Source | 100,106,000Source | 107,529,000Source | 113,632,000Source | 102,129,000Source | 109,296,000Source | 104,112,000Source | 111,027,000Source | 104,608,000Source | 78,800,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 512,000Source | -2,507,000Source | 8,427,000Source | -15,061,000Source | 904,000Source | 11,611,000Source | -5,725,000Source | 3,486,000Source | 37,364,000Source | 5,619,000Source | 15,819,000Source | 19,819,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 86,174,000Source | 64,818,000Source | 47,899,000Source | 76,585,000Source | 78,450,000Source | 37,055,000Source | 130,081,000Source | 59,401,000Source | 90,419,000Source | 63,017,000Source | 39,763,000Source | 46,856,000Source |
| Cash and Cash Equivalents, at Carrying Value | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Dividends Payable, Current | —Source | — | — | —Source | — | — | —Source | — | — | — | — | — |
| Short-term Investments | — | — | — | —Source | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -178,916,000Source | -178,652,000Source | -137,572,000Source | 367,863,000Source | 28,242,000Source | -175,218,000Source | 30,114,000Source | -609,693,000Source | -209,275,000Source | -176,494,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 6,200,000Source | 5,800,000Source | 5,900,000Source | 5,600,000Source | 6,000,000Source | 4,800,000Source | 22,200,000Source | 16,900,000Source | 10,700,000Source | 8,700,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 19,371,000Source | 15,209,000Source | 63,366,000Source | 73,968,000Source | 78,130,000Source | 120,893,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 212,046,000Source | 2,500,000Source | 56,967,000Source | 0Source | -1,410,000Source | -8,845,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 15,263,000Source | 3,069,000Source | 6,286,000Source | -5,536,000Source | 32,998,000Source | -6,589,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 13,481,000Source | -146,272,000Source | 179,552,000Source | -462,851,000Source | -153,890,000Source | -136,131,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -23,742,000Source | 76,910,000Source | -129,294,000Source | -420,072,000Source | -96,155,000Source | -5,417,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 2,148,000Source | 7,516,000Source | 22,666,000Source | 141,469,000Source | 176,737,000Source | 52,777,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -14,750,000Source | 20,634,000Source | 74,006,000Source | 870,520,000Source | 253,053,000Source | 65,186,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 54,759,000Source | 129,793,000Source | 188,517,000Source | 185,709,000Source | 201,643,000Source | 53,889,000Source | 226,548,000Source | 102,685,000Source | 110,891,000Source | 108,005,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 19,000Source | — | 0Source | 0Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 9,907,000Source | 11,000Source | 814,000Source | -3,744,000Source | 0Source | -2,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 106,000Source | -68,000Source | -401,000Source | 4,197,000Source | -122,000Source | -67,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 14,974,000Source | 11,993,000Source | 16,568,000Source | 15,081,000Source | 19,590,000Source | 14,175,000Source | 54,848,000Source | 67,097,000Source | — | — |
| Amortization of Intangible AssetsUSD | — | — | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 1,700,000Source | 1,700,000Source | 1,700,000Source | 1,700,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -4,432,000Source |
| General and Administrative ExpenseUSD | — | — | — | 30,949,000Source | — | 28,405,000Source | 46,021,000Source | 26,910,000Source | 123,943,000Source | 98,761,000Source | 92,549,000Source | 124,431,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 11,000Source | -437,000Source | 7,000Source | 1,753,000Source | 29,000Source | 103,000Source | 21,419,000Source | -2,767,000Source | 2,784,000Source | 3,785,000Source |
| InterestExpenseNonoperatingUSD | — | — | 24,562,000Source | 24,382,000Source | 23,846,000Source | 21,639,000Source | 22,505,000Source | 21,646,000Source | 89,361,000Source | 32,352,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -194,280,000Source | -175,241,000Source | -132,732,000Source | 370,445,000Source | 30,811,000Source | -173,085,000Source | -1,631,000Source | -599,493,000Source | -205,275,000Source | -176,063,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 15,364,000Source | -3,411,000Source | -4,840,000Source | -2,582,000Source | -2,569,000Source | -2,133,000Source | 31,745,000Source | -10,200,000Source | -4,000,000Source | -431,000Source |
| Nonoperating Income (Expense)USD | — | — | -8,812,000Source | -13,539,000Source | 3,695,000Source | -11,586,000Source | -12,538,000Source | -13,703,000Source | -46,813,000Source | -11,380,000Source | -1,489,000Source | 5,798,000Source |
| Operating ExpensesUSD | — | — | 245,346,000Source | 193,317,000Source | 214,997,000Source | 161,507,000Source | 223,224,000Source | 163,912,000Source | 731,102,000Source | 604,631,000Source | 445,737,000Source | 421,738,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,285,000Source | -176,000Source | -1,609,000Source | 438,000Source | 277,000Source | 341,000Source | 5,259,000Source | -1,748,000Source | 1,538,000Source | 765,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 136,933,000Source | 33,749,000Source | 796,258,000Source | 720,947,000Source | 246,141,000Source | 223,391,000Source |
| Proceeds from Contributed CapitalUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 60,000,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 46,832,000Source | 0Source | 241,388,000Source | 429,265,000Source | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 5,098,000Source | 634,000Source | 3,983,000Source | 2,389,000Source | 3,053,000Source | 5,186,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | 19,000Source | 0Source | 0Source | -80,000Source | — | — |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Amortization of Debt Issuance Costs | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation, Depletion and Amortization, Nonproduction | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Dividends Payable, Current | — | — | —Source | — | —Source | — | —Source | — | — | — | — | — |
| Gain (Loss) on Disposition of Assets | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
| Income (Loss) from Equity Method Investments | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 75,253,000Source | 27,767,000Source | 73,737,000Source | 542,709,000Source | 264,033,000Source | 2,500,000Source | 829,448,000Source | 3,551,000Source | 240,735,000Source | 243,231,000Source |
| Operating Income (Loss)USD | — | — | -170,093,000Source | -165,550,000Source | -141,260,000Source | 381,202,000Source | 40,809,000Source | -161,412,000Source | 98,346,000Source | -601,080,000Source | -205,002,000Source | -178,507,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,285,000Source | -176,000Source | -1,609,000Source | 438,000Source | 277,000Source | 341,000Source | 5,259,000Source | -1,748,000Source | 1,538,000Source | 765,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -178,905,000Source | -179,089,000Source | -137,565,000Source | 369,616,000Source | 28,271,000Source | -175,115,000Source | 51,533,000Source | -612,460,000Source | -206,491,000Source | -172,709,000Source |
| Income Tax Expense (Benefit)USD | — | — | 11,000Source | -437,000Source | 7,000Source | 1,753,000Source | 29,000Source | 103,000Source | 21,419,000Source | -2,767,000Source | 2,784,000Source | 3,785,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 15,364,000Source | -3,411,000Source | -4,840,000Source | -2,582,000Source | -2,569,000Source | -2,133,000Source | 31,745,000Source | -10,200,000Source | -4,000,000Source | -431,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -194,280,000Source | -175,241,000Source | -132,732,000Source | 370,445,000Source | 30,811,000Source | -173,085,000Source | -1,631,000Source | -599,493,000Source | -205,275,000Source | -176,063,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.36Source | -1.26Source | -0.93Source | 2.78Source | 0.22Source | -1.39Source | -0.01Source | -5Source | -1.92Source | -1.67Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.36Source | -1.26Source | -0.93Source | 2.75Source | 0.22Source | -1.39Source | -0.01Source | -5Source | -1.92Source | -1.67Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 143,378,000Source | 139,039,000Source | 142,417,000Source | 133,363,000Source | 137,039,000Source | 124,848,000Source | 133,758,000Source | 119,784,000Source | 106,750,000Source | 105,426,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 143,378,000Source | 139,039,000Source | 142,417,000Source | 134,484,000Source | 140,706,000Source | 124,848,000Source | 133,758,000Source | 119,784,000Source | 106,750,000Source | 105,426,000Source |
| Interest Expense (non-operating)USD | — | — | 24,562,000Source | 24,382,000Source | 23,846,000Source | 21,639,000Source | 22,505,000Source | 21,646,000Source | 89,361,000Source | 32,352,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 1,700,000Source | 1,700,000Source | 1,700,000Source | 1,700,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 21,419,000Source | -2,767,000Source | 2,784,000Source | 3,785,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 6,390,000Source | 5,235,000Source | 23,928,000Source | 18,595,000Source | 12,493,000Source | 10,421,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -4,432,000Source |
| General and Administrative ExpenseUSD | — | — | — | 30,949,000Source | — | 28,405,000Source | 46,021,000Source | 26,910,000Source | 123,943,000Source | 98,761,000Source | 92,549,000Source | 124,431,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | — | — | — | — | — | 51,533,000Source | -612,460,000Source | -202,491,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -42,573,000Source | -582,333,000Source | -194,639,000Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 18,326,000Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 5,033,000Source |
| Nonoperating Income (Expense)USD | — | — | -8,812,000Source | -13,539,000Source | 3,695,000Source | -11,586,000Source | -12,538,000Source | -13,703,000Source | -46,813,000Source | -11,380,000Source | -1,489,000Source | 5,798,000Source |
| Operating ExpensesUSD | — | — | 245,346,000Source | 193,317,000Source | 214,997,000Source | 161,507,000Source | 223,224,000Source | 163,912,000Source | 731,102,000Source | 604,631,000Source | 445,737,000Source | 421,738,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | 19,000Source | 0Source | 0Source | -80,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 198,223,000Source | 162,368,000Source | 173,253,000Source | 133,102,000Source | 177,203,000Source | 137,002,000Source | 607,159,000Source | — | — | — |
| Selling, General and Administrative Expense | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
| Income (Loss) from Equity Method Investments | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
Filing attachments
arwr-202608048kex991.htm · 8-K · 2026-08-04
EX-99.1 2 arwr-202608048kex991.htm EX-99.1 Document EXHIBIT 99.1 PRESS RELEASE August 4, 2026 Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results Conference Call and Webcast Today, August 4, 2026 at 4:30 p.m. ET PASADENA, Calif., August 4, 2026 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss …
Read attachment ↗arwr-202605078kex991.htm · 8-K · 2026-05-07
EX-99.1 2 arwr-202605078kex991.htm EX-99.1 Document EXHIBIT 99.1 PRESS RELEASE May 7, 2026 Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results Conference Call and Webcast Today, May 7, 2026 at 4:30 p.m. ET PASADENA, Calif., May 7, 2026 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026, at 4:30 p.m. ET to discuss the resul…
Read attachment ↗arwr-202602058kex991.htm · 8-K · 2026-02-05
EXHIBIT 99.1 PRESS RELEASE February 5, 2026 Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results Conference Call and Webcast Today, February 5, 2026 at 4:30 p.m. ET PASADENA, Calif., February 5, 2026 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is hosting a conference call today, February 5, 2026, at 4:30 p.m. ET to discuss the results. “We had another quarter of stro…
Read attachment ↗d19865dex41.htm · 8-K · 2026-01-12
EX-4.1 2 d19865dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 Execution Version ARROWHEAD PHARMACEUTICALS, INC. Debt Securities Indenture Dated as of January 12, 2026 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) …
Read attachment ↗d19865dex42.htm · 8-K · 2026-01-12
EX-4.2 3 d19865dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 ARROWHEAD PHARMACEUTICALS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of January 12, 2026 0.00% Convertible Senior Notes due 2032 CROSS REFERENCE TABLE* Trust Indenture Section Indenture Act Section 310 (a)(1) 10.09 (a)(2) 10.09 (a)(3) N/…
Read attachment ↗d94918dex41.htm · 8-K · 2026-01-09
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARROWHEAD PHARMACEUTICALS, INC. Warrant Shares: [•] Issue Date: January 9, 2026 ──────────────────────────────────────────────────────── THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial…
Read attachment ↗